The SELECT trial catapulted GLP-1 RAs into the forefront of CVD prevention, but cardiologists are making their own decisions about whether and how they might integrate these agents into practice.
Beginning today, Nicole L. Lohr, MD, PhD, FACC, will serve as chair of the American College of Cardiology Board of Governors (BOG) and secretary of th..